Epidermal Growth-Factor Receptor Expression in Malignant Ovary, Benign Ovarian-Tumors and Normal Ovary - A Comparison

Owens, OJ; Leake, R E

doi:10.3892/ijo.2.2.321

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 50%

“…Positivity for EGF-R was highest in the group of malignant common epithelial tumours, with a trend towards lower levels of positivity in the borderline-and benign-tumour groups, although this did not reach the levels of significance suggested in other studies (Owens and Leake, 1993;Berns et al, 1992;Van Dam et al, 1991). Reports of increased expression of 'I.4BLE I\'-K t L A ' I IOSSHII' BETMLEN CLISICOI'A'I'HOLOGICAI FACTORS A S D tXl'KESSlOiX O F c-erbB GROWTH-FACTOR RECEPTORS IS S1ALIGNAN'I'COM.MON EPITHELIAL O\'AKIAiX TUMOllRS Staie III/IV 3 3 11 12 Goodlmoderate differentiation 1 1 5 10 0.51 Poor differentiation 2 2 12 13 Debulked 2 1 8 17 0.29 Notipartially debulked 1 2 6 6 EGF-R in metastatic lesions as opposed to primary tumours (Henzen-Logmans et al, 1992;Battaglia et al, 1989), and in recurrent or persistent disease following chemotherapy ( Van Dam et al, 1994), might indicate an association with disease progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

c‐erbb growth‐factor‐receptor proteins in ovarian tumours

Simpson¹,

Phillips²,

Lessells

et al. 1995

Intl Journal of Cancer

View full text Add to dashboard Cite

Immunohistochemical expression of EGF-R, c-erbB-2 and c-erbB-3, members of the type-1 family of receptor tyrosine kinases, were investigated in 67 primary ovarian-tumour samples (46 malignant, 8 borderline and 13 benign), and related to tumour clinicopathological features. The incidence of all 3 receptor proteins was highest in overtly malignant tumours. No significant correlations were observed between either EGF-R or c-erbB-3 and clinical parameters such as tumour stage, differentiation or extent of debulking surgery, but c-erbB-2 was significantly associated with several indicators of prognosis, including early stage and good/moderate differentiation in optimally debulked tumours. Multiple expression of c-erbB receptor proteins was also significantly higher in malignant tumours compared with borderline and benign tumours. Early-stage tumours were also more likely to express multiple c-erbB-receptor proteins than were late-stage tumours. Co-expression of EGF-R with c-erbB-2, and c-erbB-2 with c-erbB-3 was significantly greater in malignant tumours than in borderline or benign tumours, and within the malignant tumour group, positive associations were observed between EGF-R and c-erbB-3, also between c-erbB-2 and c-erbB-3. Because of the evidence of increased expression of individual c-erbB proteins as well as multiple expression of this family of growth-factor receptors in malignant ovarian tumours, we hypothesize that stimulation by the appropriate ligands may confer a selective advantage to cells expressing more than one receptor. Increased expression of c-erbB growth-factor receptors in malignancy may mediate increased propensity for tumour development.

show abstract

Section: Discussionmentioning

confidence: 50%

Section: Discussionmentioning

confidence: 99%

c‐erbb growth‐factor‐receptor proteins in ovarian tumours

Simpson¹,

Phillips²,

Lessells

et al. 1995

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Levels of EGF receptor appear to be higher in malignant than Growth factors and ovarian cancer S P Langdon and J F Smyth ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, EH4 2XU, UK (Requests for offprints should be addressed to S Langdon) benign tumours or normal ovary, suggesting a possible biological role in malignant progression (Berns et al 1992, Owens & Leake 1993. Consistent with this, many studies have shown that its presence relates to poor prognosis in malignant tumours (Bauknecht et al 1988, Battaglia et al 1989, Berchuck et al 1991, Scambia et al 1992.…”

Section: Growth Factor Families Epidermal Growth Factor-related Peptidesmentioning

confidence: 99%

Growth factors and ovarian cancer

Langdon¹,

Smyth²

1998

Endocrine Related Cancer

View full text Add to dashboard Cite

“…Previous studies investigating the presence of EGF receptor in ovarian tumours, using either ligand binding (Bauknecht et al, 1988;Battaglia et al, 1989; Correspondence: SP Langdon *Present address: Glasgow University Department of Surgery, Level II, Queen Elizabeth Building, Glasgow Royal Infirmary, Glasgow G31 2ER, UK Owens et al, 1991a;Henzen-Logmans et al, 1992) immunohistochemical technology Morishige et al, 1991;Henzen-Logmans et al, 1992) or both (Owens et al, 1992), have indicated that this receptor is commonly present with incidence rates varying from 33% to 75% (Bauknecht et al, 1988(Bauknecht et al, , 1993Battaglia et al, 1989;Berchuck et al, 1991;Morishige et al, 1991;Owens et al, 1991a;Henzen-Logmans et al, 1992). The levels of EGF receptor have been claimed to be higher in malignant ovarian tumours than in benign tumours or the normal ovary Owens and Leake, 1993) but perhaps the strongest suggestion of a biological role for EGF-like factors derives from reports that the presence of EGF receptor protein in ovarian tumours may be related to patient prognosis (Bauknecht et al, 1988;Battaglia, 1989;Foekens et al, 1990;Berchuck et al, 1991;Scambia et al, 1992), although this has not been a universal finding (Bauknecht et al, 1990; Van der Burg et al, 1993).…”

mentioning

confidence: 99%

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

Bartlett

Langdon²,

Simpson³

et al. 1996

Br J Cancer

193

View full text Add to dashboard Cite

Summary The expression of mRNA for the epidermal growth factor (EGF) receptor, EGF and transforming growth factor a (TGF-a) was determined in 76 malignant, six borderline and 15 benign primary ovarian tumours using the reverse transcriptase-polymerase chain reaction and related to clinical and pathological parameters. Of the malignant tumours, 70% (53/76) expressed EGF receptor mRNA, 31% (23/75) expressed EGF mRNA and 35% (26/75) expressed TGF-a mRNA. For the borderline tumours, four of six (67%) expressed EGF receptor mRNA, 1/6 (17%) expressed TGF-a mRNA and none expressed EGF mRNA. Finally, 33% (5/15) of the benign tumours expressed EGF receptor mRNA, whereas 40% (6/15) expressed EGF mRNA and 7% (1/15) expressed TGF-a mRNA. The presence of the EGF receptor in malignant tumours was associated with that of TGF-a (P = 0.0015) but not with EGF (P = 1.00), whereas there was no relationship between the presence of EGF and TGF-a (P = 1.00). EGF receptor mRNA expression was significantly and positively associated with serous histology (P = 0.006) but not with stage or grade. Neither EGF nor TGF-a showed any link with histological subtype or stage. The survival of patients with malignant tumours possessing EGF receptor mRNA was significantly reduced compared with that of patients whose tumours were negative (P = 0.030 for all malignant tumours; P= 0.007 for malignant epithelial tumours only). In contrast, neither the expression of TGF-a nor EGF was related to survival. These data suggest that the presence of EGF receptor mRNA is associated with poor prognosis in primary ovarian cancer.

show abstract

Epidermal Growth-Factor Receptor Expression in Malignant Ovary, Benign Ovarian-Tumors and Normal Ovary - A Comparison

Cited by 3 publications

References 0 publications

c‐erbb growth‐factor‐receptor proteins in ovarian tumours

c‐erbb growth‐factor‐receptor proteins in ovarian tumours

Growth factors and ovarian cancer

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

Contact Info

Product

Resources

About